Krystal Biotech Inc (KRYS)
$190.4
+8.11
(+4.45%)▲
Performance
- $182.26$191.20$190.40
4.28%
Downside
Day's Volatility :4.68%
Upside
0.42%
- $99.00$219.34$190.40
48.0%
Downside
52 Weeks Volatility :54.86%
Upside
13.19%
Returns
| Period | Krystal Biotech Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -7.71% | -6.9% | 0.0% |
6 Months | 7.7% | -1.7% | 0.0% |
1 Year | 78.68% | 10.4% | 0.0% |
3 Years | 332.68% | 8.8% | -24.1% |
Highlights
Market Capitalization | 5.1B |
Book Value | $30.81 |
Earnings Per Share (EPS) | 1.78 |
PE Ratio | 98.67 |
Wall Street Target Price | 207.778 |
Profit Margin | 21.68% |
Operating Margin TTM | 41.67% |
Return On Assets TTM | 4.58% |
Return On Equity TTM | 6.38% |
Revenue TTM | 241.5M |
Revenue Per Share TTM | 8.49 |
Quarterly Revenue Growth YOY | 879.9% |
Gross Profit TTM | 0.0 |
EBITDA | 69.1M |
Diluted Eps TTM | 1.78 |
Quarterly Earnings Growth YOY | -0.67 |
EPS Estimate Current Year | 5.24 |
EPS Estimate Next Year | 6.77 |
EPS Estimate Current Quarter | 0.9 |
EPS Estimate Next Quarter | 0.9 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 9.13%
Technicals Summary
Sell
Neutral
Buy
Krystal Biotech Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Krystal Biotech Inc | 4.05% | 7.7% | 78.68% | 332.68% | 234.91% |
 Regeneron Pharmaceuticals, Inc. | -22.64% | -24.32% | -6.91% | 15.67% | 106.43% |
 Biontech Se | -2.39% | 5.8% | 10.48% | -66.36% | 407.41% |
 Alnylam Pharmaceuticals, Inc. | -16.76% | 63.55% | 51.52% | 31.97% | 130.85% |
 Vertex Pharmaceuticals Incorporated | -5.17% | 0.63% | 27.5% | 148.14% | 106.59% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Krystal Biotech Inc | 98.67 | 98.67 | NA | 5.24 | 0.06 | 0.05 | NA | 30.81 |
Regeneron Pharmaceuticals, Inc. | 18.38 | 18.38 | 1.11 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.04 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.18 | 0.54 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Krystal Biotech Inc | Buy | $5.1B | 234.91% | 98.67 | 21.68% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.7B | 106.43% | 18.38 | 33.61% |
Biontech Se | Buy | $24.5B | 407.41% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.1B | 130.85% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $116.2B | 106.59% | 32.84 | -4.51% |
Institutional Holdings
FMR Inc
14.93%BlackRock Inc
13.73%Vanguard Group Inc
9.91%venBio Select Advisor LLC
9.12%State Street Corp
4.63%Capital World Investors
3.06%
Company Information
krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)
Organization | Krystal Biotech Inc |
Employees | 229 |
CEO | Mr. Krish S. Krishnan M.B.A., M.S. |
Industry | Health Technology |
Discover More
Invesco S&p 500® Top 50 Etf
$190.40
+4.45%
Ishares 0-5 Yr High Yield Corp Bond Etf
$190.40
+4.45%
Janux Therapeutics Inc
$190.40
+4.45%
Kinetik Holdings Inc
$190.40
+4.45%
Buckle, Inc., The
$190.40
+4.45%
Cleanspark Inc
$190.40
+4.45%
Vaneck Vectors Fallen Angel Hiyld Bd Etf
$190.40
+4.45%
Borgwarner Inc.
$190.40
+4.45%
Central Garden & Pet Co A Shares
$190.40
+4.45%